The FDA has been criticised for taking more than a year to follow up a potential increase in serious adverse events in elderly people receiving Pfizer’s covid-19 vaccine.
“It’s disturbing that they have not released any of these data. If the FDA is stating publicly that they’re collecting it, then they should be publicly reporting it. They shouldn’t be burying the results in protocols as they’ve done. It’s sneaky,”
#CovidVaccine #AdverseEvents
https://www.bmj.com/content/379/bmj.o2527
“It’s disturbing that they have not released any of these data. If the FDA is stating publicly that they’re collecting it, then they should be publicly reporting it. They shouldn’t be burying the results in protocols as they’ve done. It’s sneaky,”
#CovidVaccine #AdverseEvents
https://www.bmj.com/content/379/bmj.o2527
The BMJ
FDA urged to publish follow-up studies on covid-19 vaccine safety signals
The FDA has been criticised for taking more than a year to follow up a potential increase in serious adverse events in elderly people receiving Pfizer’s covid-19 vaccine, Maryanne Demasi reports
In July 2021 the US Food and Drug Administration (FDA) quietly…
In July 2021 the US Food and Drug Administration (FDA) quietly…
SWEDEN’S Public Health Agency has recommended that the protein-based Covid-19 vaccine Nuvaxovid should not be given to people 30 years of age and younger due to increased risk of myocarditis and pericarditis.
#covidvaccine #sweden
https://euroweeklynews.com/2022/11/03/sweden-covid-vaccine-nuvaxovid-increased-risk-myocarditis-and-pericarditis/
#covidvaccine #sweden
https://euroweeklynews.com/2022/11/03/sweden-covid-vaccine-nuvaxovid-increased-risk-myocarditis-and-pericarditis/
Euro Weekly News
Sweden pauses Covid-19 vaccine Nuvaxovid for under 30s due to increased risk of myocarditis and pericarditis
Sweden has paused its Covid-19 vaccine Nuvaxovid for under 30s due to the increased risk of myocarditis and pericarditis. The decision is said to be temporary and was applied from November 2, 2022.